Genome editing using the CRISPR/Cas9 system and its application in haematology
Authors:
M. Racková 1,2; V. Bakardjieva-Mihaylova 1,2; M. Slámová 1,2; L. Boublíková 1,2; K. Škvárová Kramarzová 1,2
Authors‘ workplace:
CLIP – Childhood Leukaemia Investigation Prague
1; Klinika dětské hematologie a onkologie, 2. lékařská fakulta, Univerzita Karlova a Fakultní nemocnice Motol, Praha
2
Published in:
Transfuze Hematol. dnes,25, 2019, No. 4, p. 291-299.
Category:
Review/Educational Papers
Overview
Genome editing is considered to be the biggest advance in molecular genetics since the discovery of the polymerase chain reaction. This method enables the introduction of changes in a target DNA sequence with unprecedented accuracy and efficiency. Since it greatly facilitates the study of genes and biological processes, it has been employed in basic research across all biotechnology fields. The CRISPR/Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats/CRISPR Associated Protein 9) system is the most widely used genome-editing platform. Due to its relatively easy construction and high efficiency, this system has revolutionized the field of molecular biology and also holds enormous potential in translational medicine. The aim of this review is to introduce genome-editing technique and summarize the most important applications of this unique technology in research, diagnostics and treatment of haematologic diseases.
Keywords:
genome editing – CRISPR/Cas9 – haematology – monogenic disorders
Sources
1. Levine AJ. Virus vector-mediated gene transfer. Microbiol Sci 1987;4(8):245–250.
2. Naldini L. Genetic engineering of hematopoiesis: current stage of clinical translation and future perspectives. EMBO Mol Med 2019;11(3):E9958.
3. Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 2003;4(5):346–358.
4. Pâques F, Haber JE. Multiple pathways of recombination induced by double-strand breaks in Saccharomyces cerevisiae. Microbiol Mol Biol Rev 1999;63(2):349–404.
5. Porteus MH, Baltimore D. Chimeric nucleases stimulate gene targeting in human cells. Science 2003;300(5620):763.
6. Stoddard BL. Homing endonucleases: from microbial genetic invaders to reagents for targeted DNA modification. Structure 2011;19(1):7–15.
7. Kim YG, Cha J, Chandrasegaran S. Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain. Proc Natl Acad Sci USA 1996;93(3):1156–1160.
8. Bogdanove AJ, Voytas DF. TAL effectors: customizable proteins for DNA targeting. Science 2011;333(6051):1843–1846.
9. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier EA. programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 2012;337(6096):816–821.
10. Gasiunas G, Barrangou R, Horvath P, Siksnys V. Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proc Natl Acad Sci USA 2012;109(39):E2579–E2586.
11. Cong L, Ran FA, Cox D, et al. Multiplex genome engineering using CRISPR/Cas systems. Science 2013;339(6121):819–823.
12. Mojica FJM, Díez-Villaseñor C, García-Martínez J, Soria E. Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements. J Mol Evol 2005;60(2):174–182.
13. Barrangou R, Marraffini LA. CRISPR-Cas systems: Prokaryotes upgrade to adaptive immunity. Mol Cell 2014;54(2):234–244.
14. Redman M, King A, Watson C, King D. What is CRISPR/Cas9? Arch Dis Child Educ Pract Ed 2016;101(4):213–215.
15. Liu J-J, Orlova N, Oakes BL, et al. CasX enzymes comprise a distinct family of RNA-guided genome editors. Nature 2019;566(7743):218–223.
16. Murugan K, Babu K, Sundaresan R, Rajan R, Sashital DG. The revolution continues: Newly discovered systems expand the CRISPR-Cas toolkit. Mol Cell 2017;68(1):15–25.
17. Chang HHY, Pannunzio NR, Adachi N, Lieber MR. Non-homologous DNA end joining and alternative pathways to double-strand break repair. Nat Rev Mol Cell Biol 2017;18(8):495–506.
18. Heyer W-D, Ehmsen KT, Liu J. Regulation of homologous recombination in eukaryotes. Ann Rev Genet 2010;44(1):113–139.
19. Salsman J, Dellaire G. Precision genome editing in the CRISPR era. Biochem Cell Biol 2017;95(2):187–201.
20. Ran FA, Hsu PD, Lin C-Y, et al. Double nicking by RNA-guided CRISPR-Cas9 for enhanced genome editing specificity. Cell 2013;154(6):1380–1389.
21. Singh V, Braddick D, Dhar PK. Exploring the potential of genome editing CRISPR-Cas9 technology. Gene 2017;599:1–18.
22. González-Romero E, Martínez-Valiente C, García-Ruiz C, Vázquez-Manrique RP, Cervera J, Sanjuan-Pla A. CRISPR to fix bad blood: a new tool in basic and clinical hematology. Haematologica 2019;104(5):881–893.
23. Wang H, Yang H, Shivalila CS, et al. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell 2013;153(4):910–918.
24. Gundry MC, Brunetti L, Lin A, et al. Highly efficient genome editing of murine and human hematopoietic progenitor cells by CRISPR/Cas9. Cell Rep 2016;17(5):1453–1461.
25. Bauer DE, Canver MC, Smith EC, et al. Crispr-Cas9 saturating mutagenesis reveals an Achilles heel in the BCL11A erythroid enhancer for fetal hemoglobin induction (by genome editing). Blood 2015;126(23):638.
26. Eldridge L, Zhang L, Ye Z. Defining the role of a GATA-2 enhancer during hematopoietic differentiation of human iPSCs. Blood 2017;130(Suppl 1):4939.
27. Knudson AG. Two genetic hits (more or less) to cancer. Nat Rev Cancer 2001;1(2):157–162.
28. Reimer J, Knöß S, Labuhn M, et al. CRISPR-Cas9-induced t(11;19)/MLL-ENL translocations initiate leukemia in human hematopoietic progenitor cells in vivo. Haematologica 2017;102(9):1558–1566.
29. Torres R, Martin MC, Garcia A, Cigudosa JC, Ramirez JC, Rodriguez--Perales S. Engineering human tumour-associated chromosomal translocations with the RNA-guided CRISPR–Cas9 system. Nat Commun 2014;5(1):3964.
30. Rathe SK, Moriarity BS, Stoltenberg CB, et al. Using RNA-seq and targeted nucleases to identify mechanisms of drug resistance in acute myeloid leukemia. Sci Rep 2015;4(1):6048.
31. Shi J, Wang E, Milazzo JP, Wang Z, Kinney JB, Vakoc CR. Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains. Nat Biotechnol 2015;33(6):661–667.
32. Casanova J-L, Conley ME, Seligman SJ, Abel L, Notarangelo LD. Guidelines for genetic studies in single patients: lessons from primary immunodeficiencies. J Exp Med 2014;211(11):2137–2149.
33. Gootenberg JS, Abudayyeh OO, Lee JW, et al. Nucleic acid detection with CRISPR-Cas13a/C2c2. Science 2017;356(6336):438–442.
34. Chen JS, Ma E, Harrington LB, et al. CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity. Science 2018;360(6387):436–439.
35. Hajian R, Balderston S, Tran T, et al. Detection of unamplified target genes via CRISPR–Cas9 immobilized on a graphene field-effect transistor. Nat Biomed Eng 2019;3(6):427–437.
36. Norkin M, Wingard JR. Recent advances in hematopoietic stem cell transplantation. F1000Research 2017;6:870.
37. Badat M, Davies J. Gene therapy in a patient with sickle cell disease. N Engl J Med 2017;376(21):2093–2094.
38. Cavazzana-Calvo M, Payen E, Negre O, et al. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature 2010;467(7313):318–322.
39. Fischer A, Hacein-Bey Abina S, Touzot F, Cavazzana M. Gene therapy for primary immunodeficiencies. Clin Genet 2015;88(6):507–515.
40. Nathwani AC, Tuddenham EGD, Rangarajan S, et al. Adenovirus--associated virus vector–mediated gene transfer in hemophilia B. N Engl J Med 2011;365(25):2357–2365.
41. Dever DP, Porteus MH. The changing landscape of gene editing in hematopoietic stem cells. Curr Opin Hematol 2017;24(6): 481–488.
42. Huang X, Wang Y, Yan W, et al. Production of gene-corrected adult beta globin protein in human erythrocytes differentiated from patient iPSCs after genome editing of the sickle point mutation. Stem Cells 2015;33(5):1470–1479.
43. Xie F, Ye L, Chang JC, et al. Seamless gene correction of β-thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac. Genome Res 2014;24(9):1526–1533.
44. Skvarova Kramarzova K, Osborn M, Webber B, et al. CRISPR/Cas9-mediated correction of the FANCD1 gene in primary patient cells. Int J Mol Sci 2017;18(6):E1269.
45. Westin E, Devadasan D, Li C, Ding L, Townes TM, Goldman FD. CRISPR modification of induced pluripotent stem derived from Diamond-Blackfan anemia fibroblasts. Blood 2014;124(21):4804.
46. Chang K-H, Smith SE, Sullivan T, et al. Long-term engraftment and fetal globin induction upon BCL11A gene editing in bone-marrow-derived CD34 + hematopoietic stem and progenitor cells. Mol Ther Methods Clin Dev 2017;4:137–148.
47. Wu Y, Zeng J, Roscoe BP, et al. Highly efficient therapeutic gene editing of human hematopoietic stem cells. Nat Med 2019;25:776–783.
48. A safety and efficacy study evaluating CTX001 in subjects with severe sickle cell disease. Dostupné na: www.ClinicalTrials.gov.
49. A safety and efficacy study evaluating CTX001 in subjects with transfusion-dependent β-thalassemia. Dostupné na: www.ClinicalTrials.gov.
50. Biffi A. Hematopoietic stem cell gene therapy for storage disease: Current and new indications. Mol Ther 2017;25(5):1155–1162.
51. Moehle EA, Rock JM, Lee Y-L, et al. Targeted gene addition into a specified location in the human genome using designed zinc finger nucleases. Proc Natl Acad Sci 2007;104(9):3055–3060.
52. Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA 1993;90(2):720–724.
53. Zhou H, Luo Y, Zhu S, et al. The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis. BMC Cancer 2018;18(1):929.
54. Ren J, Liu X, Fang C, Jiang S, June CH, Zhao Y. Multiplex Cripsr/Cas9 genome editing to generate potent universal CART and PD1-deficient cells against leukemia. Blood 2015;126(23):4280.
55. Yoon DH, Osborn MJ, Tolar J, Kim CJ. Incorporation of immune checkpoint blockade into chimeric antigen receptor T Cells (CAR-Ts): Combination or built-in CAR-T. Int J Mol Sci 2018;19(2):E340.
56. Holt N, Wang J, Kim K, et al. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol 2010;28(8):839–847.
57. Li G, Zhang X, Zhong C, et al. Small molecules enhance CRISPR/Cas9-mediated homology-directed genome editing in primary cells. Sci Rep 2017;7(1):8943.
58. Zhang X-H, Tee LY, Wang X-G, Huang Q-S, Yang S-H. Off-target effects in CRISPR/Cas9-mediated genome engineering. Mol Ther Nucleic Acids 2015;4:e264.
59. Zischewski J, Fischer R, Bortesi L. Detection of on-target and off-target mutations generated by CRISPR/Cas9 and other sequence-specific nucleases. Biotechnol Adv 2017;35(1):95–104.
60. Wienert B, Wyman SK, Richardson CD, et al. Unbiased detec-tion of CRISPR off-targets in vivo using DISCOVER-Seq. Science 2019;364(6437):286–289.
61. Ihry RJ, Worringer KA, Salick MR, et al. p53 inhibits CRISPR–Cas9 engineering in human pluripotent stem cells. Nat Med 2018;24(7):939–946.
62. Conti A, Di Micco R. p53 activation: a checkpoint for precision genome editing? Genome Med 2018;10(1):66.
63. Schenkwein D, Ylä-Herttuala S. Gene editing of human embryos with CRISPR/Cas9: great promise coupled with important caveats. Mol Ther 2018;26(3):659–660.
64. Liang P, Xu Y, Zhang X, et al. CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes. Protein Cell 2015;6(5):363–372.
65. Regalado A. EXCLUSIVE: Chinese scientists are creating CRISPR babies. MIT Technol Rev 2018;Nov 25.
66. Juengst ET, Henderson GE, Walker RL, et al. Is enhancement the price of prevention in human gene editing? Cris J 2018;1(6):351–354.
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2019 Issue 4
Most read in this issue
- Characteristics and results of the treatment of patients with acute myeloid leukaemia ≥ 60 years – data from the CELL DATOOL AML database
- Genome editing using the CRISPR/Cas9 system and its application in haematology
- Mutations of the RAS family in patients with acute myeloid leukaemia
- Complex mechanisms of action of „BCR signalling“ inhibitors and development of resistance to this targeted therapy in chronic lymphocytic leukaemia